This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignee: Peking University. Active years: 2019.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2019
Title: Wenxuan Jiao: Innovator in Thiazolopyrimidinone Compounds
Introduction
Wenxuan Jiao is a notable inventor based in Beijing, China. He has made significant contributions to the field of medicinal chemistry, particularly in the development of compounds for treating central nervous system diseases. His innovative work has led to the filing of a patent that showcases his expertise and dedication to advancing medical science.
Latest Patents
Wenxuan Jiao holds a patent for "Thiazolopyrimidinone compounds and preparation methods and use thereof." This invention provides detailed structural information about thiazolopyrimidinone compounds, along with methods for their preparation. The patent also outlines the use of these compounds in the manufacture of medicaments aimed at treating various central nervous system disorders. He has 1 patent to his name, reflecting his focused contributions to this specialized area.
Career Highlights
Wenxuan Jiao is affiliated with Peking University, where he engages in research and development activities. His work at this prestigious institution allows him to collaborate with other experts in the field and contribute to groundbreaking research initiatives. His academic background and research focus have positioned him as a key figure in medicinal chemistry.
Collaborations
Wenxuan Jiao has worked alongside talented colleagues, including Kewei Wang and Qi Sun. These collaborations enhance the research environment and foster innovation in their respective fields.
Conclusion
Wenxuan Jiao's contributions to the development of thiazolopyrimidinone compounds highlight his role as an innovator in medicinal chemistry. His work not only advances scientific knowledge but also has the potential to impact the treatment of central nervous system diseases significantly.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
